Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

Pfizer's non-COVID product revenues surged 14% operationally last quarter. The oncology business delivered exceptional ...

Pfizer’s Prevnar 20 is a next-generation follow up to its more limited Prevnar 13 and competes with Merck’s Capvaxive, a newer option that scored FDA approval in June. Although Merck’s ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Further evidence from Pfizer that it is no longer dependent on income from COVID-19 products could be a catalyst for the stock to sustain a rally. I believe both Merck and Pfizer deserve a buy ...

Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Pfizer has low forward P/E ratios for the next five years. The FY2027 forward P/E ratio is low at 8.61. On the other hand, we see that the ratio will not shrink significantly between FY2024 and FY2027 ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The ...

Bank of America Securities analyst Charlie CY Yang maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s ...

Pfizer's non-COVID product revenues surged 14 ... highlighted by the strong uptake of Padcev. When combined with Merck's Keytruda (pembrolizumab), this therapy has become the most prescribed ...